mg1111

Vaccineexperimental

Clinical trial activity

4 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Mar 1, 2015 (NCT02367638)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2026

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • mg1111

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07054099Phase 3Mar 31, 2026Green Cross Corporation
NCT05664152N/AFeb 28, 2023Green Cross Corporation
NCT05422508Phase 2Jul 5, 2022Green Cross Corporation, Korea University
NCT02367638Phase 1Mar 1, 2015Green Cross Corporation
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Green Cross CorporationFor profit4442015
Korea UniversityAcademic/Hospital1012022
2 organizations
Page 1 / 1